Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 970

1.

Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy.

Chi H, Li Z, Hansen BE, Yu T, Zhang X, Sun J, Hou J, Janssen HLA, Peng J.

Clin Gastroenterol Hepatol. 2018 Jun 11. pii: S1542-3565(18)30600-1. doi: 10.1016/j.cgh.2018.05.047. [Epub ahead of print]

PMID:
29902645
2.

Microarray Expression Profiling of microRNAs Reveals Potential Biomarkers for Hepatocellular Carcinoma.

Zhu HR, Huang RZ, Yu XN, Shi X, Bilegsaikhan E, Guo HY, Song GQ, Weng SQ, Dong L, Janssen HLA, Shen XZ, Zhu JM.

Tohoku J Exp Med. 2018;245(2):89-98. doi: 10.1620/tjem.245.89.

3.

The Weibel-Palade Body Localized SNARE (Soluble NSF Attachment Protein Receptor) Syntaxin-3 Modulates Von Willebrand Factor Secretion From Endothelial Cells.

Schillemans M, Karampini E, van den Eshof B, Gangaev A, Hofman M, van Breevoort D, Meems H, Janssen H, Mulder AA, Jost CR, Escher JC, Adam R, Carter T, Koster AJ, van den Biggelaar M, Voorberg J, Bierings R.

Arterioscler Thromb Vasc Biol. 2018 Jun 7. pii: ATVBAHA.117.310701. doi: 10.1161/ATVBAHA.117.310701. [Epub ahead of print]

PMID:
29880488
4.

Hepatitis B virus infection.

Yuen MF, Chen DS, Dusheiko GM, Janssen HLA, Lau DTY, Locarnini SA, Peters MG, Lai CL.

Nat Rev Dis Primers. 2018 Jun 7;4:18035. doi: 10.1038/nrdp.2018.35. Review.

PMID:
29877316
5.

Closure of large bore 9 F arterial puncture sites with the AngioSeal STS device in acute stroke patients after intravenous recombinant tissue plasminogen activator (rt-PA).

Janssen H, Killer-Oberpfalzer M, Lange R.

J Neurointerv Surg. 2018 May 15. pii: neurintsurg-2018-013829. doi: 10.1136/neurintsurg-2018-013829. [Epub ahead of print]

PMID:
29764930
6.

96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.

Agarwal K, Brunetto M, Seto WK, Lim YS, Fung S, Marcellin P, Ahn SH, Izumi N, Chuang WL, Bae H, Sharma M, Janssen HLA, Pan CQ, Çelen MK, Furusyo N, Shalimar D, Yoon KT, Trinh H, Flaherty JF, Gaggar A, Lau AH, Cathcart AL, Lin L, Bhardwaj N, Suri V, Mani Subramanian G, Gane EJ, Buti M, Chan HLY; GS-US-320-0110; GS-US-320-0108 Investigators.

J Hepatol. 2018 Apr;68(4):672-681. doi: 10.1016/j.jhep.2017.11.039. Epub 2018 Jan 17.

PMID:
29756595
7.

Click-to-Release from trans-cyclooctenes: mechanistic insights and expansion of scope from established carbamate to remarkable ether cleavage.

Versteegen RM, Ten W, Rossin R, de Geus MA, Janssen HM, Robillard MS.

Angew Chem Int Ed Engl. 2018 May 10. doi: 10.1002/anie.201800402. [Epub ahead of print]

PMID:
29746709
8.

Selective labeling for the identification and semi-quantification of lipid aldehydes in food products.

Hollebrands B, Varvaki E, Kaal S, Janssen HG.

Anal Bioanal Chem. 2018 May 10. doi: 10.1007/s00216-018-1101-z. [Epub ahead of print]

PMID:
29744561
9.

The European Medicines Agency's approval of new medicines for type 2 diabetes.

Blind E, Janssen H, Dunder K, de Graeff PA.

Diabetes Obes Metab. 2018 May 8. doi: 10.1111/dom.13349. [Epub ahead of print] Review.

PMID:
29740935
10.

Employed family-based genetic discovery combining linkage analysis and exome sequencing to identify RCL1 as a novel candidate gene for depression, with independent replication in a population-based cohort.

Amin N, de Vrij FMS, Baghdadi M, Brouwer RWW, van Rooij JGJ, Jovanova O, Uitterlinden AG, Hofman A, Janssen HLA, Murad SD, Kraaij R, Stedehouder J, van den Hout MCGN, Kros JM, van IJcken WFJ, Tiemeier H, Kushner SA, van Duijn CM.

Mol Psychiatry. 2018 May;23(5):1093. doi: 10.1038/mp.2018.6. No abstract available.

PMID:
29731510
11.

Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice.

Rossin R, Versteegen RM, Wu J, Khasanov A, Wessels HJ, Steenbergen EJ, Ten Hoeve W, Janssen HM, van Onzen AHAM, Hudson PJ, Robillard MS.

Nat Commun. 2018 May 4;9(1):1484. doi: 10.1038/s41467-018-03880-y.

12.

Publicly Funded Oral Chronic Hepatitis B Treatment Patterns in Ontario over 16 Years: An Ecologic Study.

Tadrous M, Brahmania M, Martins D, Knowles S, Janssen HLA, Mamdani MM, Juurlink DN, Gomes T.

J Manag Care Spec Pharm. 2018 May;24(5):464-468. doi: 10.18553/jmcp.2018.24.5.464.

13.

Younger age and language barriers are associated with nonadherence to clinical follow-up in hepatitis B treatment.

Chi H, Japhary A, de Man RA, de Knegt RJ, Janssen HLA, Hansen BE.

J Viral Hepat. 2018 Apr 21. doi: 10.1111/jvh.12920. [Epub ahead of print] No abstract available.

PMID:
29679439
14.

Antimicrobial-Resistant Bacteria in Infected Wounds, Ghana, 20141.

Janssen H, Janssen I, Cooper P, Kainyah C, Pellio T, Quintel M, Monnheimer M, Groß U, Schulze MH.

Emerg Infect Dis. 2018 May;24(5):916-919. doi: 10.3201/eid2405.171506.

15.

MRI Visualization of Injectable Ureidopyrimidinone Hydrogelators by Supramolecular Contrast Agent Labeling.

Bakker MH, Tseng CCS, Keizer HM, Seevinck PR, Janssen HM, Van Slochteren FJ, Chamuleau SAJ, Dankers PYW.

Adv Healthc Mater. 2018 Jun;7(11):e1701139. doi: 10.1002/adhm.201701139. Epub 2018 Apr 15.

PMID:
29658175
16.

Synthesis and Self-Assembly of Bay-Substituted Perylene Diimide Gemini-Type Surfactants as Off-On Fluorescent Probes for Lipid Bilayers.

Schill J, van Dun S, Pouderoijen MJ, Janssen HM, Milroy LG, Schenning APHJ, Brunsveld L.

Chemistry. 2018 May 28;24(30):7734-7741. doi: 10.1002/chem.201801022. Epub 2018 May 3.

PMID:
29569314
17.

European Multicenter Study for the Evaluation of a Dual-Layer Flow-Diverting Stent for Treatment of Wide-Neck Intracranial Aneurysms: The European Flow-Redirection Intraluminal Device Study.

Killer-Oberpfalzer M, Kocer N, Griessenauer CJ, Janssen H, Engelhorn T, Holtmannspötter M, Buhk JH, Finkenzeller T, Fesl G, Trenkler J, Reith W, Berlis A, Hausegger K, Augustin M, Islak C, Minnich B, Möhlenbruch M.

AJNR Am J Neuroradiol. 2018 May;39(5):841-847. doi: 10.3174/ajnr.A5592. Epub 2018 Mar 15.

PMID:
29545252
18.

Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment.

van Campenhout MJH, van Bömmel F, Pfefferkorn M, Fischer J, Deichsel D, Boonstra A, van Vuuren AJ, Berg T, Hansen BE, Janssen HLA.

Hepatology. 2018 Mar 7. doi: 10.1002/hep.29872. [Epub ahead of print]

PMID:
29514389
19.

Effects of Treatment of Chronic HBV Infection on Patient-reported Outcomes.

Younossi ZM, Stepanova M, Janssen HLA, Agarwal K, Nguyen MH, Gane E, Tsai N, Younossi I, Racila A.

Clin Gastroenterol Hepatol. 2018 Mar 2. pii: S1542-3565(18)30225-8. doi: 10.1016/j.cgh.2018.02.037. [Epub ahead of print]

PMID:
29505905
20.

Acute basilar thrombosis: Recanalization following intravenous thrombolysis is dependent on thrombus length.

Janssen H, Brückmann H, Killer M, Heck S, Buchholz G, Lutz J.

PLoS One. 2018 Feb 21;13(2):e0193051. doi: 10.1371/journal.pone.0193051. eCollection 2018.

21.

Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population.

Papatheodoridis GV, Sypsa V, Dalekos G, Yurdaydin C, van Boemmel F, Buti M, Goulis J, Calleja JL, Chi H, Manolakopoulos S, Loglio A, Siakavellas S, Gatselis N, Keskın O, Lehretz M, Savvidou S, de la Revilla J, Hansen BE, Kourikou A, Vlachogiannakos I, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HLA, Berg T, Lampertico P.

J Hepatol. 2018 Jun;68(6):1129-1136. doi: 10.1016/j.jhep.2018.01.031. Epub 2018 Feb 8.

PMID:
29427727
22.

ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B.

Wong D, Littlejohn M, Edwards R, Jackson K, Revill P, Gaggar A, Kitrinos K, Subramanian M, Marcellin P, Buti-Ferret M, Janssen H, Gane E, Locarnini S, Thompson A.

Liver Int. 2018 Feb 10. doi: 10.1111/liv.13716. [Epub ahead of print]

PMID:
29427368
23.

Peroxiredoxin 1, restraining cell migration and invasion, is involved in hepatocellular carcinoma recurrence.

Fang Y, He J, Janssen HLA, Wu J, Dong L, Shen XZ.

J Dig Dis. 2018 Mar;19(3):155-169. doi: 10.1111/1751-2980.12580.

PMID:
29377617
24.

Correction: Quantifying exosome secretion from single cells reveals a modulatory role for GPCR signaling.

Verweij FJ, Bebelman MP, Jimenez CR, Garcia-Vallejo JJ, Janssen H, Neefjes J, Knol JC, de Goeij-de Haas R, Piersma SR, Baglio SR, Verhage M, Middeldorp JM, Zomer A, van Rheenen J, Coppolino MG, Hurbain I, Raposo G, Smit MJ, Toonen RFG, van Niel G, Pegtel DM.

J Cell Biol. 2018 Mar 5;217(3):1157. doi: 10.1083/JCB.20170320601192018c. Epub 2018 Jan 23. No abstract available.

25.

Quantifying exosome secretion from single cells reveals a modulatory role for GPCR signaling.

Verweij FJ, Bebelman MP, Jimenez CR, Garcia-Vallejo JJ, Janssen H, Neefjes J, Knol JC, de Goeij-de Haas R, Piersma SR, Baglio SR, Verhage M, Middeldorp JM, Zomer A, van Rheenen J, Coppolino MG, Hurbain I, Raposo G, Smit MJ, Toonen RFG, van Niel G, Pegtel DM.

J Cell Biol. 2018 Mar 5;217(3):1129-1142. doi: 10.1083/jcb.201703206. Epub 2018 Jan 16. Erratum in: J Cell Biol. 2018 Jan 23;:.

26.

Improved Evaluation of Antivascular Cancer Therapy Using Constrained Tracer-Kinetic Modeling for Multiagent Dynamic Contrast-Enhanced MRI.

Hectors SJ, Jacobs I, Lok J, Peters J, Bussink J, Hoeben FJ, Keizer HM, Janssen HM, Nicolay K, Schabel MC, Strijkers GJ.

Cancer Res. 2018 Mar 15;78(6):1561-1570. doi: 10.1158/0008-5472.CAN-17-2569. Epub 2018 Jan 9.

PMID:
29317433
27.

Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome.

Harms MH, Lammers WJ, Thorburn D, Corpechot C, Invernizzi P, Janssen HLA, Battezzati PM, Nevens F, Lindor KD, Floreani A, Ponsioen CY, Mayo MJ, Dalekos GN, Bruns T, Parés A, Mason AL, Verhelst X, Kowdley KV, Goet JC, Hirschfield GM, Hansen BE, van Buuren HR.

Am J Gastroenterol. 2018 Feb;113(2):254-264. doi: 10.1038/ajg.2017.440. Epub 2017 Dec 12.

PMID:
29231188
28.

Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history.

Murillo Perez CF, Goet JC, Lammers WJ, Gulamhusein A, van Buuren HR, Ponsioen CY, Carbone M, Mason A, Corpechot C, Invernizzi P, Mayo MJ, Battezzati PM, Floreani A, Pares A, Nevens F, Kowdley KV, Bruns T, Dalekos GN, Thorburn D, Hirschfield G, LaRusso NF, Lindor KD, Zachou K, Poupon R, Trivedi PJ, Verhelst X, Janssen HLA, Hansen BE; GLOBAL PBC Study Group.

Hepatology. 2018 May;67(5):1920-1930. doi: 10.1002/hep.29717. Epub 2018 Apr 6.

PMID:
29220537
29.

Identification of phase-II metabolites of flavonoids by liquid chromatography-ion-mobility spectrometry-mass spectrometry.

Chalet C, Hollebrands B, Janssen HG, Augustijns P, Duchateau G.

Anal Bioanal Chem. 2018 Jan;410(2):471-482. doi: 10.1007/s00216-017-0737-4. Epub 2017 Nov 22.

PMID:
29167932
30.

Study Design and Evaluation of Risk Minimization Measures: A Review of Studies Submitted to the European Medicines Agency for Cardiovascular, Endocrinology, and Metabolic Drugs.

Mazzaglia G, Straus SMJ, Arlett P, da Silva D, Janssen H, Raine J, Alteri E.

Drug Saf. 2018 Feb;41(2):191-202. doi: 10.1007/s40264-017-0604-4.

31.

Knockout of the Arp2/3 complex in epidermis causes a psoriasis-like disease hallmarked by hyperactivation of transcription factor Nrf2.

van der Kammen R, Song JY, de Rink I, Janssen H, Madonna S, Scarponi C, Albanesi C, Brugman W, Innocenti M.

Development. 2017 Dec 15;144(24):4588-4603. doi: 10.1242/dev.156323. Epub 2017 Nov 7.

32.

Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B.

Janssen HLA, Brunetto MR, Kim YJ, Ferrari C, Massetto B, Nguyen AH, Joshi A, Woo J, Lau AH, Gaggar A, Subramanian GM, Yoshida EM, Ahn SH, Tsai NCS, Fung S, Gane EJ.

J Hepatol. 2018 Mar;68(3):431-440. doi: 10.1016/j.jhep.2017.10.027. Epub 2017 Dec 11.

PMID:
29104121
33.

Determinants of takeaway and fast food consumption: a narrative review.

Janssen HG, Davies IG, Richardson LD, Stevenson L.

Nutr Res Rev. 2018 Jun;31(1):16-34. doi: 10.1017/S0954422417000178. Epub 2017 Oct 17.

PMID:
29037273
34.

DOTA-tetrazine probes with modified linkers for tumor pretargeting.

Läppchen T, Rossin R, van Mourik TR, Gruntz G, Hoeben FJM, Versteegen RM, Janssen HM, Lub J, Robillard MS.

Nucl Med Biol. 2017 Dec;55:19-26. doi: 10.1016/j.nucmedbio.2017.09.001. Epub 2017 Sep 14.

PMID:
29028502
35.

HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients.

Wong D, Littlejohn M, Yuen L, Jackson K, Mason H, Bayliss J, Rosenberg G, Gaggar A, Kitrinos K, Subramanian M, Marcellin P, Buti M, Janssen HLA, Gane E, Locarnini S, Thompson A, Revill PA.

Aliment Pharmacol Ther. 2018 Jan;47(1):114-122. doi: 10.1111/apt.14362. Epub 2017 Oct 11.

PMID:
29023803
36.

Oxidation of sitosterol and campesterol in foods upon cooking with liquid margarines without and with added plant sterol esters.

Lin Y, Knol D, Menéndez-Carreño M, Baris R, Janssen HG, Trautwein EA.

Food Chem. 2018 Feb 15;241:387-396. doi: 10.1016/j.foodchem.2017.08.118. Epub 2017 Sep 1.

PMID:
28958544
37.

Sclerosing angiomatoid nodular transformation of the spleen mimicking metastasis of melanoma: a case report and review of the literature.

Demirci I, Kinkel H, Antoine D, Szynaka M, Klosterhalfen B, Herold S, Janßen H.

J Med Case Rep. 2017 Sep 3;11(1):251. doi: 10.1186/s13256-017-1400-6.

38.

Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis.

Sharma SA, Kowgier M, Hansen BE, Brouwer WP, Maan R, Wong D, Shah H, Khalili K, Yim C, Heathcote EJ, Janssen HLA, Sherman M, Hirschfield GM, Feld JJ.

J Hepatol. 2017 Aug 24. pii: S0168-8278(17)32248-1. doi: 10.1016/j.jhep.2017.07.033. [Epub ahead of print]

PMID:
28844936
39.

Wait Time for Curative Intent Radio Frequency Ablation is Associated with Increased Mortality in Patients with Early Stage Hepatocellular Carcinoma.

Brahmania M, Ahmed O, Kelley M, Wong D, Kowgier M, Khalili K, Beecroft R, Renner EL, Shah H, Feld J, Janssen HLA, Sherman M.

Ann Hepatol. 2017 Sep-Oct;16(5):765-771. doi: 10.5604/01.3001.0010.2776.

40.

Hepatitis B virus infection.

Janssen HLA, Chan HLY, Petersen J.

Best Pract Res Clin Gastroenterol. 2017 Jun;31(3):237. doi: 10.1016/j.bpg.2017.05.009. Epub 2017 Jun 9. No abstract available.

PMID:
28774404
41.

Optimizing gradient conditions in online comprehensive two-dimensional reversed-phase liquid chromatography by use of the linear solvent strength model.

Graesbøll R, Janssen HG, Christensen JH, Nielsen NJ.

J Sep Sci. 2017 Sep;40(18):3612-3620. doi: 10.1002/jssc.201700239. Epub 2017 Sep 4.

PMID:
28771945
42.

Genomic, Transcriptional, and Phenotypic Analysis of the Glucose Derepressed Clostridium beijerinckii Mutant Exhibiting Acid Crash Phenotype.

Seo SO, Janssen H, Magis A, Wang Y, Lu T, Price ND, Jin YS, Blaschek HP.

Biotechnol J. 2017 Nov;12(11). doi: 10.1002/biot.201700182. Epub 2017 Oct 9.

PMID:
28762642
43.

Boredom in patients with acquired brain injuries during inpatient rehabilitation: a scoping review.

Kenah K, Bernhardt J, Cumming T, Spratt N, Luker J, Janssen H.

Disabil Rehabil. 2017 Aug 1:1-10. doi: 10.1080/09638288.2017.1354232. [Epub ahead of print]

PMID:
28760011
44.

How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach?

Rajoriya N, Combet C, Zoulim F, Janssen HLA.

J Hepatol. 2017 Dec;67(6):1281-1297. doi: 10.1016/j.jhep.2017.07.011. Epub 2017 Jul 21. Review.

PMID:
28736138
45.

Flat clathrin lattices are dynamic actin-controlled hubs for clathrin-mediated endocytosis and signalling of specific receptors.

Leyton-Puig D, Isogai T, Argenzio E, van den Broek B, Klarenbeek J, Janssen H, Jalink K, Innocenti M.

Nat Commun. 2017 Jul 13;8:16068. doi: 10.1038/ncomms16068.

46.

Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Naïve Patients.

Raj VS, Hundie GB, Schürch AC, Smits SL, Pas SD, Le Pogam S, Janssen HLA, de Knegt RJ, Osterhaus ADME, Najera I, Boucher CA, Haagmans BL.

Sci Rep. 2017 Jul 5;7(1):4688. doi: 10.1038/s41598-017-04931-y.

47.

Unique intrahepatic transcriptomics profiles discriminate the clinical phases of a chronic HBV infection.

Hou J, Brouwer WP, Kreefft K, Gama L, Price SL, Janssen HLA, French PJ, Vanwolleghem T, Boonstra A.

PLoS One. 2017 Jun 29;12(6):e0179920. doi: 10.1371/journal.pone.0179920. eCollection 2017.

48.

HBsAg loss after peginterferon-nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow-up.

Stelma F, van der Ree MH, Jansen L, Peters MW, Janssen HLA, Zaaijer HL, Takkenberg RB, Reesink HW.

J Viral Hepat. 2017 Dec;24(12):1107-1113. doi: 10.1111/jvh.12738. Epub 2017 Jul 29.

PMID:
28632898
49.

The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B.

Papatheodoridis GV, Idilman R, Dalekos GN, Buti M, Chi H, van Boemmel F, Calleja JL, Sypsa V, Goulis J, Manolakopoulos S, Loglio A, Siakavellas S, Keskın O, Gatselis N, Hansen BE, Lehretz M, de la Revilla J, Savvidou S, Kourikou A, Vlachogiannakos I, Galanis K, Yurdaydin C, Berg T, Colombo M, Esteban R, Janssen HLA, Lampertico P.

Hepatology. 2017 Nov;66(5):1444-1453. doi: 10.1002/hep.29320. Epub 2017 Oct 11.

PMID:
28622419
50.

State of Practice: Endovascular Treatment of Acute Aneurysmal SAH in Germany.

Janssen H, Berlis A, Lutz J, Thon N, Brückmann H.

AJNR Am J Neuroradiol. 2017 Aug;38(8):1574-1579. doi: 10.3174/ajnr.A5260. Epub 2017 Jun 15.

PMID:
28619838

Supplemental Content

Loading ...
Support Center